TCTP/tpt1 - Remodeling Signaling from Stem Cell to Disease
This book highlights the role of the Translationally Controlled Tumor Protein (TCTP) in cell signaling, cell fate and the resulting connection to disease development. It begins by discussing the structure/function of TCTP, before exploring its role in dif
- PDF / 11,159,267 Bytes
- 314 Pages / 439.42 x 683.15 pts Page_size
- 119 Downloads / 177 Views
Adam Telerman Robert Amson Editors
TCTP/tpt1 Remodeling Signaling from Stem Cell to Disease
Results and Problems in Cell Differentiation
Volume 64
Series editors Jacek Z. Kubiak, Rennes, France Malgorzata Kloc, Houston, TX, USA
More information about this series at http://www.springer.com/series/400
Adam Telerman • Robert Amson Editors
TCTP/tpt1 - Remodeling Signaling from Stem Cell to Disease
Editors Adam Telerman B^atiment B2M Institut Gustave Roussy Villejuif, Val-de-Marne France
Robert Amson B^atiment B2M Institut Gustave Roussy Villejuif, Val-de-Marne France
ISSN 0080-1844 ISSN 1861-0412 (electronic) Results and Problems in Cell Differentiation ISBN 978-3-319-67590-9 ISBN 978-3-319-67591-6 (eBook) DOI 10.1007/978-3-319-67591-6 Library of Congress Control Number: 2017957604 © Springer International Publishing AG 2017 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Printed on acid-free paper This Springer imprint is published by Springer Nature The registered company is Springer International Publishing AG The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland
Contents
1
2
Introduction: How We Encountered TCTP and Our Purpose in Studying It . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Adam Telerman and Robert Amson 1.1 The Initial Years: The Tumor Reversion Project . . . . . . . . . . . . 1.2 Learning to Work with High-Throughput Technology and the First Molecular Data . . . . . . . . . . . . . . . . . 1.3 The Year 2000: Giving a Decisive Turn into the Understanding of the Tumor Reversion Program . . . . . . . . . . . . . . . . . . . . . . . 1.4 The P53-TCTP Reciprocal Negative Feedback Loop and the Clinical Significance . . . . . . . . . . . . . . . . . . . . . . . . . . 1.5 Conclusion and Perspectives . . . . . . . . . . . . . . . . . . . . . . . . . . References . . . . . . . .
Data Loading...
